The Global Deuterated Drugs Market is projected to witness a rise in revenue from US$ 299.0 million in 2022 to US$ 780.7 million by 2031, growing at a compound annual growth rate (CAGR) of 11.25% during the forecast period from 2023 to 2031.
The deuterated drugs market is witnessing outstanding growth during the forecast period. This growth is due to the increasing geriatric population, rising R&D by government and healthcare institutions, and technological advancement by key players. In line with this, countries such as India, Brazil, and South Africa are witnessing significant investments in healthcare, creating a conducive environment for pharmaceutical companies to introduce deuterated drugs. As a result, this offers room for expansion to the prominent players.
A Request of this Sample Report Here- https://www.astuteanalytica.com/request-sample/deuterated-drugs-market
Deuterium is emerging as a significant trend in the drug development sector, and many experts anticipate its widespread adoption like the incorporation of fluorine in the past. Consequently, researchers are actively working on developing novel techniques to introduce deuterium into compounds, particularly those of medical relevance.
Pharmaceutical companies and investors have recognized the potential benefits of incorporating deuterium into drug molecules, which is further driving the market growth. For instance, in January 2023, Concert Pharmaceuticals was acquired by Sun Pharma for $576 million. This Mumbai-based pharmaceutical company recognized the value of deuterium drug development and made a substantial investment in acquiring Concert Pharmaceuticals, a developer of deuterated drugs.
In line with this, currently, there are twenty pharmaceutical compounds undergoing testing that contain deuterium. Out of these, sixteen compounds are deuterium-containing versions of drugs that have already been approved and used, two are deuterated versions of nutritional compounds, and two compounds were developed from the beginning with deuterium.
Unveiling the Booming Cancer Cases: Fueling Market Expansion and Opportunities
Cancer, a highly lethal disease, claimed the lives of 10 million individuals out of the reported 19.3 million cases worldwide in 2020. Predictions indicate a significant surge in cancer cases to reach 28.4 million by 2040. Traditional chemotherapy treatments have limitations such as a narrow therapeutic index, severe adverse reactions, and metabolic instability. Hence, there is an urgent demand for the development of new anticancer drugs with improved tolerability and effectiveness, as well as the modification of existing drugs to minimize toxicity and enhance efficacy. The incorporation of deuterium in certain drugs can reduce their metabolism, particularly those that undergo breakdown via hydrogen-carbon bond scission pathways.
Deuterium incorporation significantly impacts CYP450-mediated oxidative drug metabolism, which involves hydrogen-carbon bond cleavage. Deuteration of the drug extends its half-life and allows for a reduction in dosage, resulting in improved safety and efficacy. For instance, deutetrabenazine is the first deuterated form of tetrabenazine. It has been approved for treating chorea in patients with Huntington’s disease and tardive dyskinesia.
Apart from this, donafenib was specifically formulated to address various types of cancer, including hepatocellular carcinoma, colorectal cancer, and thyroid cancer. In 2021, the National Medical Products Administration of China approved the use of donafenib in the treatment of unresectable hepatocellular carcinoma. At present, numerous deuterated drugs are undergoing trials for the management of various disorders. Notably, compounds such as HC-1119, BMS-986165, AVP-786, RT001, ALK-001, and donafenib have progressed to Phase III clinical trials.
Austedo Deuterated Drug Contributing a Sizeable 43% of Market Revenue Share
Austedo has established itself as the dominant player in the market, capturing a significant market share of nearly 43%. This leadership position can be due to its remarkable efficacy, particularly in the treatment of specific medical conditions such as Huntington’s disease (HD) and tardive dyskinesia (TD). As the prevalence of these diseases continues to rise, it is expected to drive further growth in this segment.
The segment is projected to grow at a compound annual growth rate (CAGR) of 6.79% throughout the forecast period. Austedo benefits from strong backing from the global medical community, which plays a crucial role in its positive prospects. The broad acknowledgment of Austedo’s therapeutic advantages acts as a driving force behind the company’s consistent upward progression. The predicted CAGR of Austedo indicates the industry’s confidence in its continued success and widespread adoption within the healthcare industry.
North America Generated a Substantial Share of the Deuterated Drugs Market
The global market is influenced by complex dynamics across different regions, with North America leading the way. Factors such as strong research infrastructure, advanced healthcare systems, stringent regulatory frameworks, and regional variations all contribute to the global landscape of this market. In North America, the United States and Canada hold a significant share of the global market. The region’s robust research infrastructure and regulatory environment contribute to its prominence in the deuterated drugs market.
The United States plays a significant role in the deuterated drugs market, benefiting from advanced healthcare facilities, a thriving pharmaceutical industry, and a favorable environment for research and innovation. According to data from the World Health Organization (WHO), the country allocates approximately 17% of its GDP to healthcare, which has a substantial impact on the growth of the deuterated drugs market. The collaboration between academia, research institutions, and pharmaceutical companies has also contributed to a 32% increase in breakthroughs in drug formulation and delivery mechanisms over the past five years. These factors position the United States as a key contributor to the global deuterated drugs market.
For The Full Report, Please Follow This Link- https://www.astuteanalytica.com/industry-report/deuterated-drugs-market
The United States also experiences a high prevalence of conditions like Huntington’s Disease and Tardive Dyskinesia. According to the data from the CDC, over 3 million people suffer from these conditions, highlighting the importance of deuterated drugs in addressing unmet medical needs. This has contributed to a significant market growth of 22% in the past three years. The substantial patient population and the need for effective treatments have accelerated the demand for deuterated drugs in the United States.
Canada, despite having a smaller market share, holds a significant position in the regional market for deuterated drugs. The country’s advanced healthcare infrastructure, focus on research, and a notable 15% increase in collaborative efforts between different sectors have propelled Canada to become a key player in this market.
Some of the Prominent Companies are:
- Alkeus Pharmaceuticals
- Concert Pharmaceuticals
- Enanta Pharmaceuticals
- Invent Pharmaceuticals
- Lundbeck A/S
- Neuland Laboratories
- Otsuka Pharmaceuticals
- Protia LLC
- Other Prominent Players
The global deuterated drugs market segmentation focuses on Type, Application, and Region.
- Huntington’s Disease (HD)
- Tardive Dyskinesia (TD)
- North America
- The U.S.
- Western Europe
- The UK
- Rest of Western Europe
- Eastern Europe
- Rest of Eastern Europe
- Asia Pacific
- Australia & New Zealand
- South Korea
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of MEA
- South America
- Rest of South America
Get a Free Sample Report Here- https://www.astuteanalytica.com/request-sample/deuterated-drugs-market
About Astute Analytica
Astute Analytica is a global analytics and advisory company that has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in-depth and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the Globe. They are able to make well-calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment-wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising of business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron come at the top. You can be sure of best cost-effective, value-added package from us, should you decide to engage with us.
𝐆𝐞𝐭 𝐢𝐧 𝐭𝐨𝐮𝐜𝐡 𝐰𝐢𝐭𝐡 𝐮𝐬
𝐏𝐡𝐨𝐧𝐞 𝐧𝐮𝐦𝐛𝐞𝐫: +𝟏𝟖𝟖𝟖𝟒𝟐𝟗𝟔𝟕𝟓𝟕
𝐕𝐢𝐬𝐢𝐭 𝐨𝐮𝐫 𝐰𝐞𝐛𝐬𝐢𝐭𝐞: https://www.astuteanalytica.com/